Nimodipina Eg (Nimodipine)

Nimodipine, the active ingredient in Nimodipina Eg, is a calcium channel blocker (dihydropyridine) presented as an oral formulation for oral use. It is employed to prevent significant cerebral vasospasm and associated ischemic complications in patients who have suffered a subarachnoid hemorrhage.

GNH USA supplies Nimodipina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, including batch release certificates and stability data.

Nimodipine, a dihydropyridine calcium channel blocker, is employed in cerebrovascular care to address vasospastic conditions that can follow bleeding in the brain.

- Subarachnoid hemorrhage (post‑SAH): Prevention of cerebral vasospasm and related ischemic injury. - Aneurysmal subarachnoid hemorrhage: Supports neurological recovery by maintaining adequate cerebral perfusion. - Delayed cerebral ischemia: Mitigation of secondary ischemic events after hemorrhage. - Neurosurgical patients at risk of vasospasm: Helps prevent postoperative cerebral ischemia.

Adverse reactions may occur with Nimodipine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure, especially when standing. - Flushing: warm sensation and reddening of the skin. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: may lead to dizziness or syncope. - Myocardial infarction: rare but possible in susceptible patients. - Allergic reactions: rash, pruritus, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Neutropenia: marked reduction in white blood cells.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors.

- Blood pressure monitoring: check for orthostatic hypotension. - Concomitant antihypertensives: avoid additive blood‑pressure lowering effects. - Hepatic impairment: adjust use in patients with liver dysfunction. - Cardiac disease: use cautiously in recent myocardial infarction or heart failure. - Pregnancy and lactation: only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nimodipine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Concurrent antihypertensives: risk of excessive hypotension. - Other calcium‑channel blockers: additive vasodilatory effect.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - NSAIDs: potential impact on renal function. - Diuretics: may enhance hypotensive response.